B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer

Clinical Rheumatology

Volumn 29, Issue 9, 2010, Pages 1031-1035

  Bader, Lucius ^a   Koldingsnes, Wenche ^a   Nossent, Johannes ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

ANCA; Autoantibodies; B cell activating factor; Wegener's granulomatosis

Indexed keywords

B CELL ACTIVATING FACTOR; C REACTIVE PROTEIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE;

ADULT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; VASCULITIS; WEGENER GRANULOMATOSIS;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; B-CELL ACTIVATING FACTOR; C-REACTIVE PROTEIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; WEGENER GRANULOMATOSIS;

EID: 77956191919     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1526-z     Document Type: Article

References (35)

1. RA Watts MA Gonzalez-Gay SE Lane C Garcia-Porrua G Bentham DG Scott 2001 Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe Ann Rheum Dis 60 2 170 172 10.1136/ard.60.2.170 1:STN:280:DC%2BD3M7is1Wjsw%3D%3D 11156552
2. W Koldingsnes H Nossent 2000 Epidemiology of Wegener's granulomatosis in northern Norway Arthritis Rheum 43 11 2481 2487 10.1002/1529-0131(200011)43: 11<2481::AID-ANR15>3.0.CO;2-6 1:STN:280:DC%2BD3M%2FktFCjtg%3D%3D 11083271
3. N Basu R Watts I Bajema B Baslund T Bley M Boers, et al. 2010 EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis Ann Rheum Dis. 10.1136/ard.2009.119032 20448283
4. GA Preston JJ Yang H Xiao RJ Falk 2002 Understanding the pathogenesis of ANCA: where are we today? Clevel Clin J Med 69 Suppl 2 SII51 SII54 10.3949/ccjm.69.Suppl-2.SII51
5. E Csernok A Muller WL Gross 1999 Immunopathology of ANCA-associated vasculitis Intern Med 38 10 759 765 10.2169/internalmedicine.38.759 1:STN:280:DyaK1MvlsVSlsw%3D%3D 10526937
6. RA Luqmani 2007 Towards diagnostic criteria for the ANCA-associated vasculitides Clin Exp Rheumatol 25 1 Suppl 44 S57 1:STN:280: DC%2BD2s3itVWgsg%3D%3D 17428369
7. C Lapraik R Watts P Bacon D Carruthers K Chakravarty D D'Cruz, et al. 2007 BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis Rheumatology (Oxford) 46 10 1615 1616 10.1093/rheumatology/kem146a 1:STN:280:DC%2BD2srmslKluw%3D%3D
8. S Lovric U Erdbruegger P Kumpers A Woywodt C Koenecke H Wedemeyer, et al. 2009 Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients Nephrol Dial Transplant 24 1 179 185 10.1093/ndt/gfn430 1:CAS:528: DC%2BD1MXhtVKrsg%3D%3D 18685144
9. P Lamprecht A Till J Steinmann PM Aries WL Gross 2007 Current state of biologicals in the management of systemic vasculitis Ann NY Acad Sci 1110 261 270 10.1196/annals.1423.028 1:CAS:528:DC%2BD2sXht1Git7vF 17911441
10. T Dorner A Radbruch GR Burmester 2009 B-cell-directed therapies for autoimmune disease Nat Rev Rheumatol 5 8 433 441 10.1038/nrrheum.2009.141 19581902
11. F Mackay P Schneider P Rennert J Browning 2003 BAFF AND APRIL: a tutorial on B cell survival Annu Rev Immunol 21 231 264 10.1146/annurev.immunol.21. 120601.141152 1:CAS:528:DC%2BD3sXjtF2isr0%3D 12427767
12. K De Groot WL Gross K Herlyn E Reinhold-Keller 2001 Development and validation of a disease extent index for Wegener's granulomatosis Clin Nephrol 55 1 31 38 11200865
13. P Schneider F Mackay V Steiner K Hofmann JL Bodmer N Holler, et al. 1999 BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth J Exp Med 189 11 1747 1756 10.1084/jem.189.11.1747 1:CAS:528: DyaK1MXjvVSnurY%3D 10359578
14. F Mackay JL Browning 2002 BAFF: a fundamental survival factor for B cells Nat Rev Immunol 2 7 465 475 10.1038/nri844 1:CAS:528:DC%2BD38XkvFKks74%3D 12094221
15. M Krumbholz U Specks M Wick SL Kalled D Jenne E Meinl 2005 BAFF is elevated in serum of patients with Wegener's granulomatosis J Autoimmun 25 4 298 302 10.1016/j.jaut.2005.08.004 1:CAS:528:DC%2BD2MXht1Ghs7fJ 16242914
16. JS Sanders MG Huitma CG Kallenberg CA Stegeman 2006 Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse Ann Rheum Dis 65 11 1484 1489 10.1136/ard.2005.046219 1:CAS:528:DC%2BD28Xht1OjtL3P 16504995
17. A Becker-Merok C Nikolaisen HC Nossent 2006 B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time Lupus 15 9 570 576 10.1177/0961203306071871 1:CAS:528:DC%2BD28Xht1Gru7zI 17080911
18. S Bosello P Youinou C Daridon B Tolusso B Bendaoud D Pietrapertosa, et al. 2008 Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis J Rheumatol 35 7 1256 1264 1:CAS:528:DC%2BD1cXpslajtrs%3D 18528969
19. W Stohl 2003 SLE-systemic lupus erythematosus: a BLySful, yet BAFFling, disorder Arthritis Res Ther 5 3 136 138 10.1186/ar755 1:CAS:528: DC%2BD3sXjtlensb8%3D 12723979
20. RA Luqmani AR Exley GD Kitas PA Bacon 1997 Disease assessment and management of the vasculitides Baillières Clin Rheumatol 11 2 423 446 10.1016/S0950-3579(97)80052-0 1:STN:280:DyaK2szmtlOqsA%3D%3D 9220084
21. C Mukhtyar R Lee D Brown D Carruthers B Dasgupta S Dubey, et al. 2008 Modification and validation of the Birmingham Vasculitis Activity Score (version 3) Ann Rheum Dis 68 1827 1832 10.1136/ard.2008.101279 10.1136/ard.2008.101279 19054820
22. AR Exley PA Bacon RA Luqmani GD Kitas C Gordon CO Savage, et al. 1997 Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides Arthritis Rheum 40 2 371 380 10.1002/art.1780400222 1:STN:280: DyaK2s7psVGisw%3D%3D 9041949
23. R Omdal SI Mellgren W Koldingsnes EA Jacobsen G Husby 2002 Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics J Rheumatol 29 3 482 486 11908560
24. RJ Falk JC Jennette 2002 ANCA are pathogenic -oh yes they are! J Am Soc Nephrol 13 7 1977 1979 12089397
25. JC Nossent S Lester D Zahra CR Mackay M Rischmueller 2008 Polymorphism in the 5′ regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome Rheumatology (Oxford) 47 9 1311 1316 10.1093/rheumatology/ ken246 1:CAS:528:DC%2BD1cXhtV2isb3E
26. M Zhang KH Ko QL Lam CK Lo G Srivastava B Zheng, et al. 2005 Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis Int Immunol 17 8 1081 1092 10.1093/intimm/dxh287 1:CAS:528:DC%2BD2MXmvVGgsbo%3D 16000326
27. LG Ng AP Sutherland R Newton F Qian TG Cachero ML Scott, et al. 2004 B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells J Immunol 173 2 807 817 1:CAS:528:DC%2BD2cXlsVGht7o%3D 15240667
28. B Huard L Arlettaz C Ambrose V Kindler D Mauri E Roosnek, et al. 2004 BAFF production by antigen-presenting cells provides T cell co-stimulation Int Immunol 16 3 467 475 10.1093/intimm/dxh043 1:CAS:528:DC%2BD2cXhs12ktLk%3D 14978020
29. E Csernok JU Holle WL Gross 2008 Proteinase 3, protease-activated receptor-2 and interleukin-32: linking innate and autoimmunity in Wegener's granulomatosis Clin Exp Rheumatol 26 3 Suppl 49 S112 S117 1:STN:280: DC%2BD1cnotVCqsg%3D%3D 18799068
30. A Mueller K Holl-Ulrich P Lamprecht WL Gross 2008 Germinal centre-like structures in Wegener's granuloma: the morphological basis for autoimmunity? Rheumatology (Oxford) 47 8 1111 1113 10.1093/rheumatology/ken202 1:STN:280:DC%2BD1cvlsVOmsw%3D%3D
31. BR Ludviksson MC Sneller KS Chua C Talar-Williams CA Langford RO Ehrhardt, et al. 1998 Active Wegener's granulomatosis is associated with HLA-DR+CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10 J Immunol 160 7 3602 3609 1:CAS:528:DyaK1cXitFais7s%3D 9531324
32. AP Sutherland LG Ng CA Fletcher B Shum RA Newton ST Grey, et al. 2005 BAFF augments certain Th1-associated inflammatory responses J Immunol 174 9 5537 5544 1:CAS:528:DC%2BD2MXjsVerur8%3D 15843552
33. C Daridon V Devauchelle P Hutin BR Le C Martins-Carvalho B Bendaoud, et al. 2007 Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome Arthritis Rheum 56 4 1134 1144 10.1002/art.22458 1:CAS:528:DC%2BD2sXltFKgsrg%3D 17393395
34. P Szodoray P Alex MV Jonsson N Knowlton I Dozmorov B Nakken, et al. 2005 Distinct profiles of Sjogren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF Clin Immunol 117 2 168 176 10.1016/j.clim.2005.06.016 1:CAS:528:DC%2BD2MXhtVyms7jK 16126006
35. K Nakajima K Itoh K Nagatani M Okawa-Takatsuji T Fujii H Kuroki, et al. 2007 Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis Scand J Rheumatol 36 5 365 372 10.1080/03009740701286615 1:CAS:528:DC%2BD2sXht1WgsLbO 17963166